Financial Performance - The company's revenue for Q3 2022 was ¥178,726,158.13, representing a 5.39% increase compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was ¥36,945,214.13, an increase of 27.63% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,037,284.55, up 26.89% from the previous year[5]. - Total operating revenue for Q3 2022 was CNY 474,349,508.65, a decrease of 5.4% compared to CNY 501,412,396.64 in Q3 2021[21]. - Net profit for Q3 2022 reached CNY 94,643,387.92, representing an increase of 2.0% from CNY 92,766,143.34 in Q3 2021[23]. - Earnings per share for Q3 2022 were CNY 0.6487, compared to CNY 1.1527 in Q3 2021, indicating a decline of 43.7%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,804,727,873.40, reflecting a 6.58% increase from the end of the previous year[5]. - Total assets as of Q3 2022 amounted to CNY 1,804,727,873.40, an increase of 6.6% from CNY 1,693,307,837.66 at the end of Q3 2021[21]. - Total liabilities increased to CNY 353,241,072.97 in Q3 2022, up 24.3% from CNY 284,283,154.00 in Q3 2021[21]. - The company's total liabilities to equity ratio stood at 0.243, indicating a relatively low level of financial leverage[21]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥57,006,680.59, showing a significant increase of 170.88%[13]. - The net cash flow from operating activities for the period was ¥57,006,680.59, a significant improvement compared to the previous period's net cash flow of -¥80,427,600.07[24]. - Total cash inflow from operating activities was ¥461,139,874.99, while cash outflow was ¥404,133,194.40, resulting in a net cash inflow[24]. - Cash flow from investment activities was negative at -¥276,850,692.98, worsening from -¥158,106,700.89 in the previous period[24]. - The net cash flow from financing activities was ¥132,412,177.85, a recovery from the previous period's net outflow of -¥37,541,272.46[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,090[15]. - Liu Zhongliang holds 60.89% of shares, amounting to 88,162,900 shares[15]. - Total restricted shares at the end of the period is 104,964,348, with 46,650,821 shares newly restricted during the period[17]. - The company plans to lift restrictions on shares for major shareholders on August 24, 2023[17]. - Liu Zhongliang and Liu Zhongjiao are identified as siblings, indicating potential influence on shareholding dynamics[16]. Research and Development - Research and development expenses increased by 80.05% to ¥28,067,342.97, primarily due to increased costs associated with new drug development[12]. - Research and development expenses for Q3 2022 were CNY 28,067,342.97, up 80.0% from CNY 15,588,382.73 in Q3 2021, reflecting a strong focus on innovation[21]. Inventory and Fixed Assets - The company reported a significant increase in inventory, which rose by 55.38% to ¥201,200,040.41, mainly due to stockpiling by subsidiaries[10]. - Inventory increased significantly from 129,492,497.74 to 201,200,040.41, representing a growth of approximately 55.4%[19]. - Fixed assets rose from 301,928,929.86 to 545,931,172.52, an increase of around 80.8%[19]. Other Financial Metrics - The company's basic earnings per share decreased by 29.09% to ¥0.2552[5]. - The weighted average return on net assets was 2.58%, an increase of 0.49% compared to the previous year[5]. - Cash and cash equivalents decreased from 280,795,523.15 to 192,700,608.64, a decline of approximately 31.3%[19]. - Accounts receivable increased from 373,660,578.13 to 410,939,715.85, an increase of about 10%[19]. - The company received ¥80,000,000.00 in borrowings during the period, an increase from ¥50,000,000.00 in the previous period[25]. - The company paid ¥43,066,988.82 in dividends and interest, a decrease from ¥75,841,272.46 in the previous period[25]. Audit Information - The company did not conduct an audit for the third quarter report[26].

证券代码： 300878 证券简称：维康药业 浙江维康药业股份有限公司 投资者关系活动记录表 编号：2023-003 5、维康药业的核心产品基础稳固，未来增长点在哪里？ 尊敬的投资者，您好！未来公司将继续保持和发扬自身优势， 积极应对医药行业政策变化，坚持主营业务方向，全面提升经营 管理水平，加强营销网络建设，促使各项业绩指标顺利达成；同 时，公司将继续深耕医药大健康产业，并积极培育符合发展战略 的各项业务，孵化新的业绩增长点，为企业的加速发展赋能。感 谢您对公司的关注，谢谢！ 6、维康药业的银黄滴丸、罗红霉素软胶囊等产品在市场上 的表现如何？ 尊敬的投资者，您好！公司银黄滴丸用于急慢性扁桃体炎， 急慢性咽喉炎，上呼吸道感染，罗红霉素软胶囊用于化脓性链球 菌引起的咽炎及扁桃体炎，敏感菌所致的鼻窦炎、中耳炎、急性 支气管炎等。公司上述产品在其适应症领域具有良好的治疗效 果，患者认可度较高。 7、中药行业支持政策密集发布，这对维康药业的发展有什 么影响？ 尊敬的投资者，您好！以近 3 年的重点政策为例，包括 2021 年 2 月印发《关于加快中医药特色发展若干政策措施的通知》， 2022 年 3 月印发《"十四五 ...

证券代码：300878 证券简称：维康药业 浙江维康药业股份有限公司 投资者关系活动记录表 编号：2023-002 特定对象调研 □分析师会议 □媒体采访 业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 招商证券：彭可、黄辉； 人员姓名 个人投资者：庄毅智、石若强。 时间 2023 年 5 月 8 日（星期一）15:00-17:30 地点 公司接待室 董事、董事会秘书朱婷； 上市公司接待人 财务总监王静； 员姓名 证券事务代表王思。 交流内容如下： 1、业绩预告修正的原因？导致今年归母净利润同比降幅 约 50%的原因是什么？ 投资者关系活动 答：（1）随着公司年度审计工作的深入，部分业务活动 主要内容介绍 的会计处理结果与前期预告时产生差异。经与年审会计师沟通 达成一致后，对中药材贸易业务等进行调整，该调整导致公司 业绩预告中的财务指标出现更正。 （2）随着大健康产业园一期项目的陆续投入使用，导致 折旧成本较大增加；受疫情影响，公司药品销售量有所下降， 为促进公司产品销售，公司加大了产品促销力度，给予客户更 大的价格优惠。 2、医药大 ...

证券代码：300878 证券简称：维康药业 公告编号：2023-019 浙江维康药业股份有限公司 关于参加浙江辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江维康药业股份有限公司（以下简称 "公司"）将参加由浙江证监局、浙江省上市公司协会与深圳市全景网络有限公 司联合举办的"2023 年浙江辖区上市公司投资者集体接待日活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与 本次互动交流，活动时间为 2023 年 5 月 12 日（周五）15:00-17:00。届时公司高 管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 浙江维康药业股份有限公司 董事会 2023 年 5 月 8 日 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 195,738,788.54, representing a 6.50% increase compared to CNY 183,784,056.82 in the same period last year[5] - Net profit attributable to shareholders was CNY 27,526,041.93, up 20.10% from CNY 22,919,976.17 year-on-year[5] - Net profit for Q1 2023 reached CNY 28,017,798.79, representing a growth of 21.5% from CNY 23,128,425.85 in Q1 2022[19] - The total comprehensive income for the first quarter of 2023 was CNY 28,017,798.79, an increase from CNY 23,128,425.85 in the same period last year, representing a growth of approximately 21.5%[20] - The net profit attributable to the parent company was CNY 27,526,041.93, compared to CNY 22,919,976.17 in the previous year, marking an increase of about 20.2%[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 13,486,613.08, a 273.94% increase from a negative CNY 7,753,792.32 in the previous year[5] - Cash inflows from operating activities totaled CNY 138,651,727.79, while cash outflows amounted to CNY 125,165,114.71, resulting in a net cash inflow of CNY 13,486,613.08[23] - The company reported cash and cash equivalents at the end of the period amounting to CNY 211,590,625.68, an increase from CNY 193,666,223.27 at the end of the previous period[23] - Cash received from government subsidies related to operating activities increased by 45.51% to CNY 3,993,821.22 from CNY 2,744,671.41 year-on-year[9] - The company raised CNY 88,240,496.00 through financing activities, with a net cash flow from financing activities of CNY 86,855,234.10[23] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,018,407,162.08, a 5.47% increase from CNY 1,913,773,127.42 at the end of the previous year[5] - Current liabilities totaled CNY 452,929,636.38, an increase of 9.7% from CNY 412,995,292.72 in the previous year[16] - The total liabilities increased to CNY 579,451,606.33, compared to CNY 502,254,330.46 in the previous year, showing a growth of 15.4%[16] - Long-term borrowings rose significantly to CNY 71,633,846.16, compared to CNY 33,393,350.16 in the same quarter last year, indicating a growth of 114.4%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,215[11] - Liu Zhongliang holds 60.89% of shares, amounting to 88,162,900 shares, while Liu Zhongjiao holds 6.82% with 9,872,030 shares[11] - The total number of restricted shares at the end of the period is 104,853,289, with 111,060 shares released during the period[12] - The total number of preferred shareholders is not applicable for this reporting period[12] Expenses and Costs - Total operating costs for Q1 2023 were CNY 165,096,759.61, up from CNY 162,915,922.80 in the same period last year, reflecting a slight increase of 1.3%[18] - Research and development expenses for Q1 2023 were CNY 8,841,656.30, up from CNY 7,808,286.33, reflecting a 13.2% increase year-over-year[19] - The company reported a significant increase in financial expenses, which rose to CNY 1,269,264.90, a 2018.35% increase compared to CNY 59,917.73 last year[9] Investment and Income - Investment income grew by 186.02% to CNY 5,959,695.88, compared to CNY 2,083,670.00 in the previous year[9] - The company reported an investment income of CNY 5,959,695.88, which is a substantial increase from CNY 2,083,670.00 in Q1 2022[19] Other Information - The company has no new product or technology developments mentioned in the reports[11][12][13] - There are no significant market expansion or acquisition strategies outlined in the reports[11][12][13] - The company has not provided specific future outlook or performance guidance in the available documents[11][12][13] - The company has not disclosed any other new strategies in the reports[11][12][13] - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[24]

Financial Performance - The company's operating revenue for 2022 was ¥531,291,689.13, a decrease of 16.06% compared to ¥632,953,240.27 in 2021[16]. - The net profit attributable to shareholders for 2022 was ¥44,444,260.14, down 53.94% from ¥96,495,377.13 in 2021[16]. - The net profit after deducting non-recurring gains and losses was ¥19,205,655.02, a decline of 77.37% from ¥84,873,492.32 in 2021[16]. - The company reported a significant quarterly revenue drop in Q4 2022, with revenue of ¥56,942,180.48, down from ¥178,726,158.13 in Q3 2022[18]. - The net profit attributable to shareholders in Q4 2022 was a loss of ¥49,486,684.47, contrasting with profits in the previous three quarters[18]. - In 2022, the company achieved total operating revenue of CNY 531,291,689.13, a decrease of 16.06% compared to CNY 632,953,240.27 in 2021[50]. - The net profit attributable to shareholders was CNY 44,444,260.14, reflecting a significant decline in profitability amid market challenges[50]. - The pharmaceutical manufacturing segment generated CNY 307,303,462.34, accounting for 57.84% of total revenue, down 12.83% year-over-year[52]. - The pharmaceutical wholesale and retail segment saw an increase in revenue to CNY 220,956,527.12, up 12.54% from the previous year[52]. - The company reported a total sales volume of 27,900,446 boxes in 2022, a decrease of 19.78% from 34,781,672 boxes in 2021[55]. Research and Development - The company emphasizes R&D investment and talent acquisition, with a commitment to developing new drugs in areas such as antibiotics and gynecology[30]. - The company has established multiple research platforms, including provincial high-tech enterprise research centers and Nobel Prize workstations, to enhance its core competitiveness in the pharmaceutical field[29]. - The company is advancing multiple R&D projects, including the secondary development of Yinhuang Diban and the research on Jin Qian Cao capsules, aiming to enhance product lines and revenue contributions[62]. - The company plans to submit applications for several new traditional Chinese medicine products, enhancing its product portfolio[62]. - The company is currently developing new products in the pharmaceutical sector, including traditional Chinese medicine extracts[78]. - The company is focusing on new drug research and development in areas such as antibiotics, heat-clearing and detoxifying drugs, and gynecological products, aiming for high-tech content and high market share[85]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's board and management, ensuring accountability[3]. - The company’s board of directors has fully attended the meeting to review the annual report, reflecting governance diligence[3]. - The company held its annual general meeting with a participation rate of 74.60% on June 6, 2022, and subsequent temporary meetings with participation rates of 73.72% and 74.40% in August and October 2022, respectively[103]. - The board of directors diligently fulfilled their responsibilities, ensuring compliance with regulations and promoting effective decision-making[134]. - The company is committed to maintaining transparency and accountability in its financial disclosures[134]. - The company has a complete organizational structure with independent management rights, ensuring no interference from the controlling shareholder in operational activities[101]. Risk Management - The company emphasizes potential risks in production and operations, including policy risks, drug quality control risks, R&D innovation risks, and management risks due to rapid expansion[3]. - The company has strengthened its internal control systems, enhancing supervision and evaluation to mitigate operational risks[155]. - No significant internal control deficiencies were reported during the period[159]. Market Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is experiencing growth due to supportive national policies and increasing health awareness[26]. - The company plans to leverage the favorable policies for traditional Chinese medicine to enhance its market position and product offerings[27]. - The company aims to enhance its market presence through the acquisition of local pharmacy chains[47]. - The company is actively expanding its product pipeline with several new traditional Chinese medicine formulations under development[39]. - The company is focusing on expanding its pharmaceutical wholesale and retail operations to improve overall revenue performance[50]. Financial Management - The company plans to not distribute cash dividends, issue bonus shares, or increase capital stock from capital reserves for the 2022 fiscal year, opting to carry forward undistributed profits to the next year[153]. - The total cash dividend amount, including other methods, was reported as 0 yuan, representing 0.00% of the total profit distribution[151]. - The company emphasized the importance of retaining profits for future business expansion and R&D projects, citing significant funding needs for growth[153]. - The company plans to implement a cash distribution policy where cash dividends will account for at least 20% of the distributable profits if there are no major investment plans or cash expenditures[146]. Employee Management - The company has established a competitive salary system to enhance employee income levels and share the results of corporate development[141]. - The company emphasizes talent development and has created a comprehensive training system to improve employee skills and meet the demands of rapid growth[143]. - The total number of employees at the end of the reporting period was 1,082, with 513 in the parent company and 569 in major subsidiaries[140]. Compliance and Social Responsibility - The company strictly adheres to environmental protection laws and regulations, implementing energy-saving and environmentally friendly practices in daily operations[162]. - The company actively fulfills social responsibilities, ensuring the protection of shareholder interests, especially for minority shareholders, and creating a good working environment for employees[163]. - The company complies with labor laws, providing employees with social insurance and a harmonious labor relationship[165]. Future Outlook - Future guidance indicates a projected revenue growth of 18% for 2023, driven by new product introductions and market expansion[183]. - The management has provided guidance for 2023, projecting a revenue growth of 12%[113]. - The company plans to launch three new products in the next fiscal year, targeting a market share increase of 5%[118].

浙江维康药业股份有限公司 2022 年第三季度报告 证券代码：300878 证券简称：维康药业 公告编号：2022-057 浙江维康药业股份有限公司 2022 年第三季度报告 （一） 主要会计数据和财务指标 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 浙江维康药业股份有限公司 2022 年第三季度报告 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 178,726,158.13 | 5.39% | 4 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥295,623,350.52, a decrease of 10.91% compared to ¥331,830,356.46 in the same period last year[18]. - The net profit attributable to shareholders was ¥56,985,730.48, down 10.64% from ¥63,771,086.30 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was ¥43,859,687.92, representing an 18.43% decline from ¥53,767,845.88 in the previous year[18]. - Basic and diluted earnings per share decreased by 50.32% to ¥0.394 from ¥0.793 in the previous year[18]. - The company reported a total comprehensive income of CNY 55,187,728.27 for the first half of 2022, compared to CNY 62,487,228.37 in the same period of 2021[182]. - The company reported a net profit of 64,300,000 CNY for the first half of 2022, an increase of 13.5% year-over-year[190]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥28,079,294.36, compared to a negative cash flow of ¥61,793,890.39 in the same period last year, marking a 145.44% increase[18]. - Cash and cash equivalents decreased to CNY 204.37 million, representing 12.06% of total assets, down 4.52% from the previous year[58]. - The cash flow from operating activities was negative, indicating a cash outflow of 78,416,589.08 CNY during the reporting period[187]. - The total assets of the company at the end of the reporting period were 1,200,000,000 CNY, up from 1,100,000,000 CNY in the previous year[191]. Research and Development - Research and development expenses rose by 92.54% to ¥17,851,124.42, primarily due to increased outsourcing of R&D[52]. - The company is investing 100 million RMB in R&D for innovative drug formulations over the next two years[107]. - The company is focusing on expanding its marketing network, with a project budget of CNY 2.14 million for network construction[64]. - The company has committed to several projects, including a pharmaceutical health industry park, with a total investment of CNY 45.58 million planned[64]. Market Strategy and Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[107]. - The company plans to expand its market presence by entering three new provinces in China by the end of 2022, aiming for a 20% market share in these regions[113]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for this purpose[107]. - The company has outlined a strategic goal to achieve a 50% increase in production capacity by 2024[108]. Shareholder and Dividend Policies - The company plans not to distribute cash dividends or issue bonus shares[4]. - Zhejiang Weikang Pharmaceutical Co., Ltd. is committed to maintaining shareholder dividends, with a proposed payout ratio of 30% of net profits[107]. - The company distributed dividends totaling 42,585,738.83 CNY during the reporting period[187]. Risk Management - The company faced various risk factors, which are detailed in the report, and investors are advised to be aware of these risks[3]. - The company has established a comprehensive quality management system to mitigate risks related to drug quality control[75]. - Management risks associated with rapid expansion are being addressed through training and recruitment of management personnel[78]. Regulatory Compliance and Governance - The company adheres to regulatory requirements for drug and biological product disclosures as per the Shenzhen Stock Exchange guidelines[39]. - The company complies with labor laws and regulations, ensuring the protection of employees' legal rights and interests[91]. - The company has not reported any significant changes in the feasibility of its projects[66]. Innovation and Product Development - The company has established multiple research platforms, including provincial high-tech enterprise research centers and Nobel Prize workstations, enhancing its core competitiveness in the pharmaceutical field[29]. - The company is committed to R&D in antibiotic, heat-clearing, detoxifying, and gynecological fields, emphasizing technology and market demand[29]. - The company has several ongoing research projects, including the "Yinhuang Duwan" in Phase II clinical trials, with the completion of all cases reported on March 28, 2022[39]. Corporate Social Responsibility - The company actively fulfills social responsibilities, ensuring the protection of shareholders' interests, especially those of minority shareholders[89]. - The company has been actively involved in social welfare activities, including health consultations and donations of epidemic prevention materials[93].

Financial Performance - The company's operating revenue for 2021 was approximately ¥632.95 million, representing a 1.64% increase compared to ¥622.77 million in 2020[12]. - The net profit attributable to shareholders decreased by 28.95% to approximately ¥96.50 million from ¥135.82 million in 2020[12]. - Basic and diluted earnings per share fell by 40.89% to ¥1.20 from ¥2.03 in 2020[12]. - The total assets of the company increased by 3.96% to approximately ¥1.69 billion from ¥1.63 billion at the end of 2020[12]. - The net assets attributable to shareholders rose by 1.16% to approximately ¥1.40 billion from ¥1.38 billion at the end of 2020[12]. - The weighted average return on net assets decreased to 6.98% from 16.37% in 2020, a decline of 9.39%[12]. - The company reported a total revenue of 5.486 billion RMB for the year 2021[126]. - The company achieved a net profit attributable to shareholders of RMB 96,495,377.13 for the year 2021, with a cumulative undistributed profit of RMB 496,643,671.33 from the previous year[160]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[134]. - The company reported a total revenue of 1.5 billion CNY for the year 2021, representing a year-over-year growth of 12%[198]. Cash Flow and Investments - The net cash flow from operating activities turned negative at approximately -¥67.74 million, a decline of 258.24% compared to ¥42.81 million in 2020[12]. - The company reported a net increase in cash and cash equivalents of -¥314,057,175.91, a decline of 171.47% year-on-year[69]. - Investment activities generated a net cash flow of -¥192,349,728.49, an increase of 11.65% in losses compared to the previous year[68]. - The company has committed to invest in a healthcare industrial park with a total investment of 45,582.9 million yuan, of which 39,892.0 million yuan has been utilized as of June 30, 2022, achieving a utilization rate of 87.52%[75]. - The company has also committed to a marketing network project with a total investment of 2,143 million yuan, fully utilized as of June 30, 2022, reflecting a utilization rate of 34.33%[75]. Research and Development - The company focuses on R&D in antibiotics, heat-clearing and detoxifying drugs, and gynecological products, emphasizing innovation and market demand[25]. - The company has established multiple research platforms, including provincial high-tech enterprise research centers and post-doctoral workstations, to enhance its core competitiveness in the pharmaceutical field[25]. - Research and development expenses increased by 81.37% to ¥37,015,323.92, attributed to increased outsourcing of R&D activities[64]. - The company is currently conducting clinical trials for the secondary indication of Yinhuang Diban, aiming to enhance product competitiveness and revenue contribution[65]. - The company is advancing core R&D projects, including innovative traditional Chinese medicine and modified new drugs, with a focus on increasing R&D investment and team stability[87][88]. Market Strategy and Expansion - The company plans to optimize market layout and enhance internal management to address challenges posed by economic downturns and ongoing healthcare reforms[56]. - The company is focusing on expanding its market presence and enhancing product development in response to competitive pressures[56]. - The company plans to enter two new regional markets in 2022, aiming for a market share increase of 5% in those areas[182]. - The company is expanding its marketing network across key provinces to support the growing demand for existing and new products[93]. - A strategic acquisition of a local competitor is planned, which is anticipated to enhance market share by 10%[134]. Quality Control and Compliance - The company faces risks including policy risks, drug quality control risks, and management risks due to rapid expansion[4]. - The company has implemented a comprehensive quality management system covering all operational aspects from R&D to sales[43]. - The company adheres to high-quality standards, with all products exceeding national standards set by the Pharmacopoeia of the People's Republic of China[43]. - The company emphasizes quality in its procurement process, ensuring that all purchased drugs come from qualified suppliers[36]. - The company has established a comprehensive new drug research and development system to mitigate risks associated with high-tech pharmaceutical products, including thorough market research and strict control at all stages of development[99]. Governance and Management - The company maintains an independent and complete business system, ensuring no interference from controlling shareholders in decision-making and operational activities[106]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[107]. - The company has established a complete organizational structure with independent management authority, including a shareholders' meeting, board of directors, supervisory board, and a management team led by the general manager[118]. - The management team emphasizes the importance of maintaining high-quality standards in production and compliance with regulatory requirements[126]. - The company has implemented a performance evaluation system for senior management, linking their performance directly to compensation[110]. Employee and Social Responsibility - The total number of employees at the end of the reporting period was 1,100, with 564 in the parent company and 536 in major subsidiaries[155]. - The company emphasizes the protection of employee rights and has established a harmonious labor relationship by providing social insurance and benefits[173]. - The company actively engages in social responsibility initiatives, including health consultations and charitable activities, especially during the COVID-19 pandemic[174]. - The company has a strategic focus on enhancing employee motivation and creativity through salary adjustments[157]. - The company has a diverse professional composition among its workforce, with a significant number in sales and production roles[156]. Future Outlook - The company plans to execute a stock repurchase program, with a maximum amount not exceeding 20% of the net profit attributable to shareholders of the parent company from the previous fiscal year[184]. - The company has set ambitious targets for revenue growth in the next fiscal year, aiming for a percentage increase compared to the previous year[126]. - Future guidance estimates a revenue growth of 12% for 2022, projecting total revenue of approximately 1.34 billion yuan[194]. - The company is committed to sustainability initiatives, aiming for a 50% reduction in carbon emissions by 2025[195]. - The company aims to strengthen its operational efficiency and improve financial performance in the upcoming fiscal year[126].

Financial Performance - The company's operating revenue for Q1 2022 was ¥183,784,056.82, representing a 38.96% increase compared to ¥132,259,899.28 in the same period last year[4] - The net profit attributable to shareholders was ¥22,919,976.17, up 13.06% from ¥20,272,669.37 year-on-year[4] - Basic and diluted earnings per share increased by 12.00%, from ¥0.25 to ¥0.28[4] - The net profit for the first quarter of 2022 was CNY 23,128,425.85, an increase of 13.6% compared to CNY 20,371,610.56 in the same period last year[20] - The total profit for the first quarter was CNY 26,301,735.68, up from CNY 23,793,837.35, reflecting a growth of 10.6% year-over-year[20] - The operating profit increased to CNY 26,209,232.01 from CNY 23,685,671.98, marking a rise of 10.6%[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching -¥7,753,792.32, an 82.77% increase from -¥45,004,162.70 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 7,753,792.32, an improvement from a net outflow of CNY 45,004,162.70 in the previous year[23] - Cash and cash equivalents at the end of the period were CNY 193,666,223.27, down from CNY 484,957,165.65 at the end of the previous year[24] - The company reported cash inflows from operating activities totaling CNY 162,034,979.37, compared to CNY 137,497,389.46 in the same period last year[23] - Total cash outflows from operating activities were CNY 169,788,771.69, a decrease from CNY 182,501,552.16 year-over-year[23] - Investment activities resulted in a net cash outflow of CNY 77,998,619.91, compared to CNY 49,228,549.30 in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,698,866,952.67, a slight increase of 0.33% from ¥1,693,307,837.66 at the end of the previous year[4] - The company's cash and cash equivalents at the end of Q1 2022 were CNY 193,666,223.27, down from CNY 280,795,523.15 at the beginning of the year[16] - Accounts receivable increased to CNY 425,360,607.31 from CNY 373,660,578.13, indicating a rise of 13.8%[16] - Total liabilities decreased to CNY 275,458,017.59 from CNY 284,283,154.00, a reduction of 3.0%[17] - The company's retained earnings increased to CNY 535,619,956.63 from CNY 512,699,980.46, reflecting a growth of 4.5%[18] - The total equity attributable to shareholders rose to CNY 1,420,231,036.79 from CNY 1,397,311,060.62, an increase of 1.6%[18] Research and Development - The company reported a significant increase in R&D expenses, which rose by 90.83% to ¥7,808,286.33, reflecting increased investment in outsourced R&D projects[10] - Research and development expenses for Q1 2022 amounted to CNY 7,808,286.33, representing a 91.5% increase from CNY 4,091,733.61 in Q1 2021[19] Operating Costs - The company’s gross profit margin was impacted by a 97.42% increase in operating costs, which reached ¥88,408,553.56 due to rising raw material prices[10] - The total operating costs for Q1 2022 were CNY 162,915,922.80, up 51.7% from CNY 107,306,551.41 in Q1 2021[19] - The gross profit margin for Q1 2022 was approximately 11.4%, down from the previous year's margin due to increased costs[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,705, with the largest shareholder holding 60.89% of the shares[12] Government Support - The company received government subsidies amounting to ¥753,142.87, contributing to a 64.99% increase in other income to ¥926,038.72[10] Audit Information - The company did not conduct an audit for the first quarter report[25]